Thymic Stromal Lymphopoietin Protein (TSLP) (Transcript Variant 1)

N° du produit ABIN2734446

Cette protéine Recombinant Thymic Stromal Lymphopoietin est produite dans Escherichia coli (E. coli).

Aperçu rapide pour Thymic Stromal Lymphopoietin Protein (TSLP) (Transcript Variant 1) (ABIN2734446)

Antigène: Thymic Stromal Lymphopoietin (TSLP)

Type de proteíne: Recombinant

Origine: Humain

Source: Escherichia coli (E. coli)

Application: Antibody Production (AbP), Standard (STD)

Pureté: > 95 % as determined by SDS-PAGE and Coomassie blue staining

Détail du produit

Attributs du protein: Transcript Variant 1

Attributs du produit:

• Recombinant human TSLP (transcript variant 1) protein expressed in E. coli.
• Produced with end-sequenced ORF clone

niveau d'endotoxine: Endotoxin level is <0.1 ng/μg of protein (<1EU/μg).

Information d'application

Indications d'application: Recombinant human proteins can be used for:
Native antigens for optimized antibody production
Positive controls in ELISA and other antibody assays

Restrictions: For Research Use only

Stockage

Buffer: Lyophilized from a 0.2 μM filtered solution of 20 mM phosphate buffer,100 mM NaCl, pH 7.2

Conseil sur la manipulation: Resuspend the protein in the desired concentration in proper buffer

Stock: -80 °C

Stockage commentaire: Store at -80°C. Thaw on ice, aliquot to individual single-use tubes, and then re-freeze immediately. Only 2-3 freeze thaw cycles are recommended.

Détail du antigène

Antigène: Thymic Stromal Lymphopoietin (TSLP)

Autre désignation: Tslp

Sujet: This gene encodes a hemopoietic cytokine proposed to signal through a heterodimeric receptor complex composed of the thymic stromal lymphopoietin receptor and the IL-7R alpha chain. It mainly impacts myeloid cells and induces the release of T cell-attracting chemokines from monocytes and enhances the maturation of CD11c(+) dendritic cells. The protein promotes T helper type 2 (TH2) cell responses that are associated with immunity in various inflammatory diseases, including asthma, allergic inflammation and chronic obstructive pulmonary disease. The protein is therefore considered a potential therapeutic target for the treatment of such diseases. Alternative splicing of this gene results in multiple transcript variants.

Poids moléculaire: 15 kDa

NCBI Accession: NP_149024